Helix BioPharma Corp.: Helix Biopharma Corp. Responds to Market Activity
RICHMOND HILL, ON / ACCESSWIRE / January 13, 2021 / Helix BioPharma Corp. (TSX:HBP) ( Helix or the Company ), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology, based on its proprietary technological platform DOS47, wishes to confirm that it is not aware of any material, undisclosed information related to the Company that would account for the recent increase in the market price and level of trading volume of its ordinary shares.
About Helix BioPharma Corp.
Helix BioPharma Corp. is an immuno-oncology company specializing in the field of cancer therapy. Helix is a biopharmaceutical company developing unique therapies in the field of immuno-oncology, for the prevention and treatment of cancer, based on its proprietary technology platform DOS47. Helix is currently listed on the TSX under the symbol HBP . For more information: https://www.helixbiopharma.com
Helix BioPharma Corp. Closes Private Placement
RICHMOND HILL, ON / ACCESSWIRE / December 30, 2020 / Helix BioPharma Corp. (TSX:HBP) ( Helix or the Company ), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology, based on its proprietary technological platform DOS47, today announced it has closed a private placement financing for gross proceeds of $3,000,000.
The terms of the placement are for the purchase of units at $0.50 per unit. Each unit is comprised of one common share and one common share purchase warrant. Each common share purchase warrant will entitle the holder to purchase one common share at an exercise price of $0.70 and have an expiry of five years from the date of issuance. Helix intends to use the net proceeds of the private placement for working capital and research and development activities.
Helix BioPharma Corp. Finalizes Polish Subsidiary Divestiture
RICHMOND HILL, ON / ACCESSWIRE / December 22, 2020 / Helix BioPharma Corp. (TSX:HBP) ( Helix or the Company ), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology based on its proprietary technological platform DOS47, today announced that it has closed the transaction with CAIAC Fund Management AG ( CAIAC ) for the Company s remaining holdings in its Polish subsidiary, Helix Immuno-Oncology S.A. ( HIO ), for gross proceeds of PLN 6,700,000 (CAD $2,308,000).
As announced on November 9, 2020, the Company signed a definitive agreement with CAIAC to purchase Helix s remaining holdings in HIO.
On August 28, 2020, CAIAC, as portfolio manager for Biotech Opportunity Fund ( Opportunity Fund ), announced that it acquired control and direction over, and Opportunity Fund had acquired beneficial ownership of, 26,363,172 common shares of the Company, representing approximately 19.